Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP418101.RAzxxZUNCF90Z3i7UeBk1NSj7hryTbjkoLTMcxBwBlxrI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP418101.RAzxxZUNCF90Z3i7UeBk1NSj7hryTbjkoLTMcxBwBlxrI130_assertion type Assertion NP418101.RAzxxZUNCF90Z3i7UeBk1NSj7hryTbjkoLTMcxBwBlxrI130_head.
- NP418101.RAzxxZUNCF90Z3i7UeBk1NSj7hryTbjkoLTMcxBwBlxrI130_assertion description "[Nineteen percent (19/100) of those with haemophilia A and 37% (6/16) with haemophilia B developed inhibitors at 12-18 mo of age, after exposure to FVIII/FIX concentrates for an average of 14 d in the case of haemophilia A and 16 d in haemophilia B.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP418101.RAzxxZUNCF90Z3i7UeBk1NSj7hryTbjkoLTMcxBwBlxrI130_provenance.
- NP418101.RAzxxZUNCF90Z3i7UeBk1NSj7hryTbjkoLTMcxBwBlxrI130_assertion evidence source_evidence_literature NP418101.RAzxxZUNCF90Z3i7UeBk1NSj7hryTbjkoLTMcxBwBlxrI130_provenance.
- NP418101.RAzxxZUNCF90Z3i7UeBk1NSj7hryTbjkoLTMcxBwBlxrI130_assertion SIO_000772 12222714 NP418101.RAzxxZUNCF90Z3i7UeBk1NSj7hryTbjkoLTMcxBwBlxrI130_provenance.
- NP418101.RAzxxZUNCF90Z3i7UeBk1NSj7hryTbjkoLTMcxBwBlxrI130_assertion wasDerivedFrom befree-20140225 NP418101.RAzxxZUNCF90Z3i7UeBk1NSj7hryTbjkoLTMcxBwBlxrI130_provenance.
- NP418101.RAzxxZUNCF90Z3i7UeBk1NSj7hryTbjkoLTMcxBwBlxrI130_assertion wasGeneratedBy ECO_0000203 NP418101.RAzxxZUNCF90Z3i7UeBk1NSj7hryTbjkoLTMcxBwBlxrI130_provenance.